Vinod Pullarkat, MD
Enriched profileProfessor, Department of Hematology and Hematopoietic Cell Transplantation · City of Hope National Medical Center
Vinod Pullarkat is Professor, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope National Medical Center. OpenAlex indexes 564 publications with 15,934 citations (h-index 54); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 10 Oct 2026
Overview
Updated 16 Oct 2026
Vinod Pullarkat, M.D., is Professor, Department of Hematology and Hematopoietic Cell Transplantation at City of Hope National Medical Center, Duarte, CA. The public record shows 564 publications with 15,934 citations (h-index 54), centered on Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 37 companies.
- Most recent indexed publication: 2026 · Leukemia & lymphoma
- Top research focus: Acute Myeloid Leukemia Research
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 37 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 44 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 163.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sponsor: City of Hope Medical Center
- 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: City of Hope Medical Center
- Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Sponsor: City of Hope Medical Center
Industry payments
Updated 16 Oct 2026
37 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year202519 payments$42,178openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year202535 payments$35,987openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202511 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
53.2%Factor Xa inhibitor22.1%Eliquis71%Xarelto29%Part D<11 patientsVitamin K antagonist16%Warfarin Sodium100%Part D≥23 patients+ 2 more classes in this area
Cancer & immunology
28.2%Kinase inhibitor24.4%Jakafi83%Iclusig17%Part D<11 patientsBCL-2 Inhibitor3.8%Venclexta100%Part D<11 patientsAnti-infectives
9.7%Short-acting sulfonamides6.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsHepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor3.6%Entecavir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
112 congress contributions (2005–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Clinical outcomes of adults with PAX5-mutated or rearranged B-cell acute lymphoblastic leukemia.
Leukemia & lymphoma
Article2026 - Clinical Implications of CD19-Negative Relapse Following CD19-Directed Therapy in B-Cell Acute Lymphoblastic Leukemia.
American journal of hematology
Article2026 - Allogeneic heamatopoietic stem cell transplant in patients with refractory T-cell large granular lymphocytic leukaemia: A single-centre experience.
British journal of haematology
Article2026 - B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy.
British journal of haematology
Article2026 - Long-Term Outcomes of Stem Cell Transplant in Older Patients With Acute Myeloid Leukemia Treated With Venetoclax-Based Therapies.
American journal of hematology
Letter2026
Most-cited works
by citation count (OpenAlex)- 01Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaArticle2,884 citations2020
- 02
- 03
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
MRCP
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →education.binaytara.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sumanta Pal, MD
City of Hope National Medical Center
Joanne Mortimer, MD
City of Hope National Medical Center
Tanya Dorff, MD
City of Hope National Medical Center
Alex Herrera, MD
City of Hope National Medical Center
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center